 |
|
|
|
 |
|
|
| Article 1 to 10 out of 58 concerning MorphoSys AG
|
-
MorphoSys Granted Further Patent on its Core Antibody Technology in Japan
(16 Mar 2010)
MorphoSys AG announced that the Japanese Patent Office has granted a new patent providing extended protection for the Company's core technology HuCAL. The new patent (JP 4436457) covers the production and design of an antibody library based on phage ...
-
Galapagos and MorphoSys expand antibody alliance
(18 Feb 2010)
Galapagos NV and MorphoSys AG announced that they have expanded their antibody alliance in bone & joint diseases. Based on the progress made so far, the partners have agreed to add another antibody target to the alliance, thereby increasing the ...
-
AbD Serotec Expands Sales Office in Düsseldorf to Increase Sales Activities in Europe and Asia
(10 Feb 2010)
MorphoSys AG announced that its research and diagnostic antibodies unit AbD Serotec will expand its sales organization in Düsseldorf to support growth in continental and eastern Europe as well as in Asia. The official opening ceremony was performed ...
-
Wacker and MorphoSys expand Cooperation to use Wacker's ESETEC Technology for Production of Antigen Material
(22 Jan 2010)
Wacker Chemie AG and MorphoSys AG announced an expansion of their existing cooperation in the use of Wacker s bacterial secretion technology ESETEC®. As a result, MorphoSys will now be able to use the Wacker technology for the production of antigen ...
-
MorphoSys Enrolls First Patient in Phase 1b/2a Clinical Trial for MOR103 Program in Rheumatoid Arthritis
(20 Jan 2010)
MorphoSys AG announced that it has enrolled the first patient in its Phase 1b/2a clinical trial of its lead drug MOR103. The Company's lead development program, MOR103, is a fully human HuCAL antibody directed against GM-CSF (granulocyte ...
-
Galapagos receives EUREKA innovation label and OSEO funding
(27 Nov 2009)
Galapagos NV announced that its antibody therapeutics program with MorphoSys and SARM program have been awarded funding by the French governmental organization OSEO. Accordingly, the Paris-based Galapagos R&D center will receive interest free loans ...
-
Dr. Simon Moroney Awarded Bavarian State Medal for Outstanding Services to the Bavarian Economy
(26 Nov 2009)
MorphoSys AG announced that its co-founder and CEO Dr. Simon Moroney was awarded the Bavarian State Medal for Outstanding Services to the Bavarian Economy. The award ceremony took place at the Bavarian State Ministry of Economy, Infrastructure, ...
-
MorphoSys Receives Regulatory Approval to Start Phase 1b/2a Clinical Trial for MOR103 Program
(10 Nov 2009)
Germany's Paul-Ehrlich-Institute Approves Clinical Trial in Rheumatoid Arthritis Patients
MorphoSys AG announced that it has received clearance from Germany's Paul-Ehrlich-Institute as well as a positive opinion from the ethics committees in Germany to commence a Phase 1b/2a human clinical trial in patients with rheumatoid arthritis ...
-
MorphoSys and Daiichi Sankyo Forge Alliance to Develop Novel Antibody Therapies against Hospital-Acquired Infections
(21 Oct 2009)
MorphoSys AG announced the formation of a new alliance with Daiichi Sankyo Company, Limited in the discovery and development of therapeutic antibodies for hospital-acquired (nosocomial) infections. Daiichi Sankyo becomes MorphoSys's first ...
-
MorphoSys Appoints Head of Clinical Development
(17 Sep 2009)
MorphoSys AG announced the appointment of Lisa Rojkjaer, MD, as Vice President and Head of Clinical Development. Dr. Rojkjaer joins MorphoSys from Novartis Pharma AG where she most recently held the position of Head of Medical Affairs - ...
Additional information
MorphoSys AG
Martinsried/Planegg, Germany
Company
|
|
|
|
|
|
Top
